Evotec SE (NASDAQ:EVO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET

Company Participants

Werner Lanthaler - Chairman and Chief Executive Officer

Cord Dohrmann - Chief Scientific Officer

Craig Johnstone - Chief Operating Officer

Enno Spillner - Chief Financial Officer

Conference Call Participants

James Quigley - Morgan Stanley

Joseph Hedden - Rx Securities

Falko Friedrichs - Deutsche Bank

Igor Kim - Berenberg

Michael Ryskin - Bank of America

Zoe Karamanoli - RBC Capital Markets

Operator

Dear ladies and gentlemen, welcome to the conference call of Evotec SE. At our customers’ request, this conference will be recorded. [Operator Instructions] May I now hand you over to Dr. Werner Lanthaler, CEO who will lead you through this conference? Please go ahead.

Werner Lanthaler

Thank you. This is Werner from Evotec. Welcome from sunny Hamburg. We have uploaded a presentation to follow this conference call that should help you to go through last year’s events into this year where we say setting the pace. We have uploaded this presentation to the web and you can follow this presentation throughout this event.

When you go to Page #2 of this presentation, let me start by not only introducing my team, but first of all, also thanking my team. I am here together with Craig and Cord and our CFO, Enno and it is a great pleasure to make another year together with you and close out another year together with you. And we could close out nothing together if we wouldn’t have a fantastic company together and behind us.

So let me also take before we go into content, take this opportunity and thank the whole company wholeheartedly for another fantastic year that we have completed as Evotec in 2021. This year brought us closer to our mission where research would never stop until all diseases can be treated more precisely than they are treated now. We have been shifting gears up in ‘21 to follow our mission stronger than ever.

If you go to Page #4 of this presentation, let us first briefly look back into the last year, which marks many highlights, but also some lowlights. But overall, it marks a fantastic year following our long-term strategy, which we call Action Plan 2025, The R&D Autobahn to Cures. Highlights of ‘21 can be marked by multiple new and extended integrated deals. The opening of our J.POD in Redmond, the initiation of our J.POD in Toulouse, very good progress in our co-owned pipeline, which we call Evotec royalty pool, because the long-term mission behind it is to have a co-owned pipeline with royalty inflow to Evotec.